2/28/2019 8:42:30 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) FY19 Rev. Estimate To 20.0 M From 125.5 M
2/28/2019 8:42:19 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) Q4 19 Rev. Estimate To 5.0 M From 31.4 M
2/28/2019 8:42:13 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) Q3 19 Rev. Estimate To 5.0 M From 31.4 M
2/28/2019 8:42:08 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) Q2 19 Rev. Estimate To 5.0 M From 31.4 M
2/28/2019 8:41:59 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) Q1 19 Rev. Estimate To 5.0 M From 31.4 M
2/28/2019 8:41:41 AM
Wedbush Is Cutting Voyager Therapeutics (VYGR) FY19 Estimate To -2.18 From 1.39
2/28/2019 8:41:13 AM
Wedbush Is Cutting Voyager Therapeutics (VYGR) Q4 19 Estimate To -0.63 From 0.31
2/28/2019 8:41:02 AM
Wedbush Is Lowering Voyager Therapeutics (VYGR) Q3 19 Estimate To -0.56 From 0.34
2/28/2019 8:40:50 AM
Wedbush Is Cutting Voyager Therapeutics (VYGR) Q2 19 Estimate To -0.49 From 0.37
2/28/2019 8:40:39 AM
Wedbush Is Cutting Voyager Therapeutics (VYGR) Q1 19 Estimate To -0.50 From 0.37
2/22/2019 8:06:01 AM
AbbVie And Voyager Collaborate To Develop Vectorized Antibodies To Treat Parkinson's Disease And Other Synucleinopathies
1/29/2019 7:07:31 AM
Neurocrine Biosciences And Voyager Therapeutics Form Strategic Collaboration
1/22/2019 7:05:59 AM
Voyager Therapeutics Appoints Robert Hesslein As General Counsel
1/7/2019 7:19:32 AM
Voyager Therapeutics Provides Update To Its VY-AADC Clinical Program For Parkinson’s Disease
12/10/2018 7:11:43 AM
Voyager First Patient Dosed In RESTORE-1, Phase 2 Trial Of VY-AADC Gene Therapy For Treatment Of Parkinson’s Disease